Cytokinetics to Participate in September Investor Conferences

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) has announced its participation in three major investor conferences in September 2024:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 7:45 AM ET
• H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 10:30 AM ET
• Cantor Fitzgerald Global Healthcare Conference 2024 on September 18 at 9:10 AM ET

All events will take place in New York City. Live webcasts of the presentations and fireside chats will be available on the Cytokinetics website, with replays archived for 90 days after each event. This participation demonstrates Cytokinetics' commitment to investor relations and provides opportunities for the company to showcase its developments to a wide audience of healthcare investors.

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in September:

• Morgan Stanley 22^nd Annual Global Healthcare Conference: Cytokinetics will participate in a fireside chat on Wednesday, September 4, 2024 at 7:45 AM Eastern Time at the New York Marriott Marquis Hotel in New York, NY.
• H.C. Wainwright 26^th Annual Global Investment Conference: Cytokinetics will present on Monday, September 9, 2024 at 10:30 AM Eastern Time at the Lotte New York Palace Hotel in New York, NY.
• Cantor Fitzgerald Global Healthcare Conference 2024: Cytokinetics will participate in a fireside chat on Wednesday, September 18, 2024 at 9:10 AM Eastern Time at the InterContinental New York Barclay Hotel in New York, NY.
  

Interested parties may access the live webcasts of the presentation and fireside chats by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replays will be archived on the Cytokinetics website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

What investor conferences is Cytokinetics (CYTK) attending in September 2024?

Cytokinetics (CYTK) is attending three investor conferences in September 2024: Morgan Stanley Global Healthcare Conference on September 4, H.C. Wainwright Global Investment Conference on September 9, and Cantor Fitzgerald Global Healthcare Conference on September 18.

When and where is Cytokinetics (CYTK) presenting at the H.C. Wainwright conference?

Cytokinetics (CYTK) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 10:30 AM Eastern Time at the Lotte New York Palace Hotel in New York, NY.

How can investors access Cytokinetics (CYTK) presentations at these conferences?

Investors can access live webcasts of Cytokinetics (CYTK) presentations and fireside chats by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. Webcast replays will be archived on the website for 90 days following each event.

What type of event is Cytokinetics (CYTK) participating in at the Morgan Stanley conference?

Cytokinetics (CYTK) will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, at 7:45 AM Eastern Time at the New York Marriott Marquis Hotel.